In triple negative breast cancer, PTPN13, the transcriptional target gene of SMYD2, could be phosphorylated by SMYD2 and link SMYD2 to breast cancer associated signaling pathways, such as ERK, and mTOR signaling pathways, further affected breast cancer growth [31]. Here, PTPN13 is linked to triple-negative breast carcinoma.